We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANDA Backlog, OPQ, Abuse-Deterrent Opioids Among Top CDER Priorities
ANDA Backlog, OPQ, Abuse-Deterrent Opioids Among Top CDER Priorities
Addressing the ANDA backlog, setting up the pharmaceutical quality office, and issuing final guidance on abuse-deterrent opioids are among the roughly dozen top priorities for CDER in 2015.